HONG KONG – Marking another step forward for South Korea's leading biosimilar developer, the Ministry of Food and Drug Safety (MFDS) approved domestic sales of Samsung Bioepis Co. Ltd.'s Renflexis (infliximab), a biosimilar of Johnson & Johnson's Remicade (infliximab). This is the second marketing approval for the company this year.
HONG KONG – South Korea's Ministry of Science, ICT, and Future Planning has big plans for the biotech and med-tech industries, with plans to invest tens of millions of dollars into 10 companies. The aim of the ministry's plan is to provide a strong springboard to spur sector growth in South Korea. It would include investments of 80 million won (US$68.3 million) for the next three years.
HONG KONG – South Korea's Ministry of Science, ICT, and Future Planning has big plans for the biotech and med-tech industries, with plans to invest tens of millions of dollars into 10 companies.
HONG KONG – Amgen Inc., one of the four largest U.S. biopharmaceutical companies, recently launched Amgen Korea, a move that coincided with the go-ahead to market two cancer drugs in the country.
HONG KONG – Amgen Inc., one of the four largest U.S. biopharmaceutical companies, recently launched Amgen Korea, a move that coincided with the go-ahead to market two cancer drugs in the country.
HONG KONG – In a deal with a South Korean biotech, French pharma major Sanofi SA is collecting more diabetes drugs for its pipeline, aiming to mitigate the impact on its diabetes business, which has seen a 6.6 percent decline in the global market.
